tbuckley/cabot-search huggingface dataset:
A phase I open-label study to investigate safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MT-5111 in subjects with HER-2 positive tumors.
Authors: Brian Andrew Van Tine, Minal A. Barve, Erika Paige Hamilton, Andrew Jacob Brenner, Zev A. Wainberg, Christine Burnett, Josh Pelham, Brigitte Brieschke, Thomas Strack
Journal: Journal of Clinical Oncology (2020)

TPS465 Background: Engineered toxin bodies (ETBs) are proprietarily engineered from a Shiga-like Toxin A subunit fused to antibody-like binding domains. ETBs can force receptor internalization, self-route to the cytosol, and induce cell-kill via inactivation of ribosomes. MT-5111 is a 55 kDa de-immunized ETB targeting HER2, and may not be subject to resistance mechanisms that exist for TKI, ADC, or antibodies. It binds a HER2 epitope distinct from trastuzumab or pertuzumab, could be combined with other HER2 targeting agents, and may have improved tumor penetration. Methods: MT-5111 is evaluated as monotherapy in subj with confirmed HER2+ locally advanced or metastatic cancers. The primary objective is to determine the maximum tolerated dose in subjects (subj) with advanced HER2-positive tumors. Secondary endpoints are PK, tumor response and immunogenicity. Part 1 will escalate doses to identify MTD in up to 42 subj. Part 2 will further evaluate MT-5111 at the MTD in up to 98 subj. All subj will receive MT-5111 on Days 1, 8, and 15 of each 21-day cycle until disease progression, unacceptable toxicity, death, withdrawal of consent or another reason for withdrawal. Part 1 will include subj with any HER2+ solid cancers. Part 2 will enroll 3 expansion cohorts: HER2+ breast (BC), HER2+ gastroesophageal cancer (GEA), and other HER2+ solid cancers. HER2+ must be demonstrated on metastatic lesions in case of metastases. Tumors tested by immunohistochemistry (IHC) must have IHC status of 2+ or 3+, regardless of in-situ hybridization (ISH) results; for BC and GEA, if no IHC is available, ISH per ASCO-CAP guidelines is used. Subj with HER2+ BC should have had at least 2 lines of HER2-directed therapy; subj with HER2+ gastric cancer should have received trastuzumab or have been intolerant to trastuzumab. Subj with evaluable disease may be included in Part 1; in Part 2, all subj must have at least 1 measurable lesion per RECIST 1.1. ECOG should be 0-1, and bone marrow, hepatic, renal, cardiac function should be adequate. Further details can be found on clinicaltrials.gov (NCT04029922). Enrollment has begun in September 2019. Clinical trial information: NCT04029922.
Endless education
Authors: R. Salzberg
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction: Celastrol Suppresses Angiogenesis-Mediated Tumor Growth through Inhibition of AKT/Mammalian Target of Rapamycin Pathway
Authors: Xiufeng Pang, Zhengfang Yi, Jing Zhang, Binbin Lu, Bokyung Sung, Weijing Qu, Bharat B. Aggarwal, Mingyao Liu
Journal: Cancer Research (2019)

In the original version of this article (1), images of experimental controls in Figs. 2B, 2C, and 3A are the same as those in Figs. 4B, 4C, and 3A, respectively, in a previously published article (2). The authors explained that the experiments were intentionally designed so that the same controls could be used to test different experimental conditions, and the best representative images were selected to generate these figures. In addition, two different images representing p70S6K1/S6K Western blot bands were presented in Figs. 5B and 6C, respectively. In both figures, the lower bands are redundant. The errors have been corrected in the latest online HTML and PDF versions of the article. Finally, the same β-actin Western blot image was duplicated in Fig. 6B. The lower image is incorrect, but the authors are unable to provide the original data. However, the editors have determined that this error does not change the major findings of the article. The authors regret these errors.
Stay Safe
Authors: Michelle M. Kittleson
Journal: Annals of Internal Medicine (2021)

Ad LibitumApril 2021Stay SafeMichelle M. Kittleson, MD, PhDMichelle M. Kittleson, MD, PhDCedars Sinai, Los Angeles, CaliforniaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M20-1275 Audio Reading - “Stay Safe” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads “Stay Safe” by Michelle M. Kittleson, MD, PhD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Until now, I've shunnedthose sentimental signoffs:Regards, Warmly, Best.Until now, I've closede-mails simply, with just adash and then Michelle.Until now, I've rolledmy eyes: Best what, exactly?No need for that sap.Now, I yearn for theluxury of my pettye-mail vexations.Now, Stay safe is myshorthand for all the things Icannot bear to say.Stay safe from illness,doctor becoming patient,contagion from care.Stay safe from bringingthe virus home; a vectorto those who love you.Stay safe from extremesof quarantine: loved onestoo close, or too far.Stay safe from burdensof mounting bills and fallingfunds; no end in sight.Stay safe from the ... Author, Article, and Disclosure InformationAffiliations: Cedars Sinai, Los Angeles, CaliforniaCurrent Author Address: Michelle M. Kittleson, MD, PhD, 8536 Wilshire Boulevard, Suite 301, Los Angeles, CA 90211; e-mail, michelle.[email protected]org. PreviousarticleNextarticle Advertisement Audio Reading - “Stay Safe” Audio. Michael A. LaCombe, MD, Annals Associate Editor, reads “Stay Safe” by Michelle M. Kittleson, MD, PhD Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics April 2021Volume 174, Issue 4Page: 566 ePublished: 20 April 2021 Issue Published: April 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Impaired hepatocyte cell division induces progenitor cell activation and emergence of bi-phenotypic hepatocytes
Authors: Gözde Zafer, Jin Rong Ow, Matthew Dewhurst, Noémi K.M. Van Hul, Matias Caldez, Christine Goh, Nai Yang Fu, Philipp Kaldis
Journal: Journal of Hepatology (2020)
Pyogenic arthritis caused by a total parenteral nutrition line
Authors: K. Kudsk
Journal: JAMA (1979)

THE INCIDENCE of catheter-related sepsis during total parenteral nutrition (TPN) can be reduced<sup>1</sup>to 1% to 2% when several principles are observed: (1) aseptic catheter placement by qualified personnel; (2) meticulous line care, with use of antiseptic ointment and an occlusive dressing; and (3) maintenance of an absolutely closed infusion system.<sup>2</sup>Constant surveillance is essential to ensure early diagnosis of TPN-related sepsis, but verification that the central line is the cause of fever is not easy. The majority of patients have ongoing infections, and cultures of most suspected catheters are in fact negative.<sup>3</sup> Aware of these facts, several authors have suggested that catheter removal be delayed 12 to 24 hours after the onset of fever if no obvious cause is found, and even longer if an infectious process can be confirmed and treated. Even when guidelines for line management are carefully observed, physicians must suspect central lines
Prostatectomía por via perineal
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply:
Authors: Radhakrishna K. Rao
Journal: Hepatology (2009)

I thank Dr. Fujita for raising an important issue of difficulties in measuring endotoxemia. The concern regarding the interfering factors in measuring plasma endotoxin by limulus amebocyte lysate (LAL) assay is well taken. The difficulties in measuring plasma endotoxin are due to the inhibitory factors present in samples, the variability due to the type of lysate used, and variability caused by different standards used this assay. Therefore, it is imperative to improve the LAL assay method to avoid interfering factors. Several approaches have been attempted to minimize the interference by inhibitors. Extraction of endotoxin from the sample,1 treatment of samples with chloroform to remove inhibitors, or dilution of samples to tone down the inhibitory effects2 are some of these approaches. Endotoxin assay, however, in experimental setups is likely to yield valuable information. As discussed in the review,3 there was a consistent 5-fold to 20-fold increase in endotoxin level following ethanol feeding, despite the variability in the levels of plasma endotoxin measured in different studies. Similarly, a high level of plasma endotoxin was recorded in patients with alcoholic liver disease (ALD) compared to normal subjects when similar extraction methods, lysate, and standards were used. Therefore, comparison of data in different groups within a study is very useful. However, the use of endotoxin values to determine the state of endotoxemia in individual subjects and in diagnostic or prognostic applications in the clinic is still premature. A more controlled and reliable assay needs to be developed for this purpose. Regarding the anti-endotoxin therapy, the issue is much more complicated. The evidence suggests that intestinal barrier function and endotoxin-mediated liver injury are some of the initial events in the pathogenesis of ALD. Therefore, once endotoxin has triggered the cascade of injurious events in the liver, following it with anti-endotoxin therapy may not be very effective. However, anti-endotoxin therapy may be useful in preventive measures and to attenuate the recurrence of disease. Finally, Dr. Fujita is right about the view that endotoxemia is not the only culprit in the pathogenesis of ALD. Experimental evidence is clear that ethanol and endotoxin in combination are much more dangerous than each of them alone. Nevertheless, evidence is clear that endotoxemia is one of the major factors that are involved in the pathogenesis of ALD. Radhakrishna K. Rao*, * Department of Physiology, University of Tennessee, Memphis, TN.
Serologic therapy of tetanus in the United States, 1965-1971
Authors: P. A. Blake
Journal: JAMA (1976)

To study the influence of tetanus antitoxins on the outcome of human tetanus, we analyzed data on 545 cases reported to the Center for Disease Control from 1965 through 1971. Patients treated with antitoxin had a significantly lower case-fatality ratio than untreated patients, and the effect of serotherapy was not modified significantly by the age or race of the subjects. Antitoxin of equine origin and human tetanus immune globulin (TIG) were equally effective. The data on the effect of different doses of TIG suggest that 500 units may be as effective as the currently recommended therapeutic dose of 3,000 to 10,000 units. The importance of possible bias introduced by unmeasured factors such as quality of supportive therapy could not be determined, but confounding by 11 recorded potentially confounding factors was minimal. (<i>JAMA</i>235:42-44, 1976)
Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer
Authors: Daniel Nava Rodrigues, Pasquale Rescigno, David Liu, Wei Yuan, Suzanne Carreira, Maryou B. Lambros, George Seed, Joaquin Mateo, Ruth Riisnaes, Stephanie Mullane, Claire Margolis, Diana Miao, Susana Miranda, David Dolling, Matthew Clarke, Claudia Bertan, Mateus Crespo, Gunther Boysen, Ana Ferreira, Adam Sharp, Ines Figueiredo, Daniel Keliher, Saud Aldubayan, Kelly P. Burke, Semini Sumanasuriya, Mariane Sousa Fontes, Diletta Bianchini, Zafeiris Zafeiriou, Larissa Sena Teixeira Mendes, Kent Mouw, Michael T. Schweizer, Colin C. Pritchard, Stephen Salipante, Mary-Ellen Taplin, Himisha Beltran, Mark A. Rubin, Marcin Cieslik, Dan Robinson, Elizabeth Heath, Nikolaus Schultz, Joshua Armenia, Wassim Abida, Howard Scher, Christopher Lord, Alan D’Andrea, Charles L. Sawyers, Arul M. Chinnaiyan, Andrea Alimonti, Peter S. Nelson, Charles G. Drake, Eliezer M. Van Allen, Johann S. de Bono
Journal: Journal of Clinical Investigation (2018)
Treatment of Central Sleep Apnea
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Efficacy of radionuclide scanning in patients with lung cancer
Authors: R. J. Kelly
Journal: JAMA (1979)

Ninety-two patients with histologically proved carcinoma of the lung were studied retrospectively to determine the usefulness of liver, brain, and bone imaging in their examination and treatment. Occult metastatic liver disease was observed in two (5.3%) of 38 asymptomatic patients, while four (6.6%) of 58 neurologically intact patients had abnormal brain scans. Eight (13.6%) of 59 asymptomatic patients had metastatic bone disease. Seven (18.4%) of 38 patients with no clinical evidence of metastatic disease to liver, brain, or bone had at least one type of abnormal radionuclide study. More than half (52.5%) of the patients studied had at least one abnormal scan exclusive of symptoms. Radionuclide imaging is a useful procedure in the initial evaluation and subsequent management of lung cancer. (<i>JAMA</i>242:2855-2857, 1979)
Cardiovascular diseases remain nation's leading cause of death
Authors: P. Gunby
Journal: JAMA (1992)

THE SO-CALLED graying of America literally is becoming a heartfelt problem. This is especially true for the nation's women. At a seminar this week in Galveston, Tex, American Heart Association officials cited their own and federal government data indicating that one in nine women aged 45 to 64 years in this country has some form of heart or blood vessel disease. That ratio climbs to one in three women who are aged 65 years or older. <h3>Science Reporters' Forum</h3> These officials used the association's 19th forum for science reporters (<i>JAMA</i>. 1987;258:2197, 2202, 2211) to point out also that—although men have a greater risk of developing hypertension while younger—when persons of either sex reach 55 years of age, the risk of high blood pressure becomes approximately equal. And, says the association, after age 65, women are more likely to develop high blood pressure than men. More than half of all women
Abstract 1516: HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers
Authors: Takuya Murata, Takayuki Enomoto, Yutaka Ueda, Kiyoshi Yoshino, Shigeo Yagi, Robert M. Hoffman, Hiroto Mizushima, Tadashi Kimura, Eisuke Mekada
Journal: Cancer Research (2012)

Abstract Tumor stroma drives the growth and progression of cancers. A heparin-binding epidermal growth factor-like growth factor, HB-EGF, is an EGF receptor ligand that stimulates cell growth in an autocrine or paracrine fashion. While elevated expression of HB-EGF in cancer cells and its contribution to tumor progression are well documented, the effects of HB-EGF expression in the tumor stroma have not been clarified. Here, we show that HB-EGF is expressed in stromal fibroblasts where it promotes tumor cell proliferation. In uterine cervical cancers, HB-EGF was detected immunohistochemically in the stroma proximal to the cancer epithelium. Proliferation of cervical cancer cells in vitro was enhanced by coculture with fibroblasts isolated from tumor tissues of patients with cervical cancer. Inhibition of HB-EGF function or treatment with platelet-derived growth factor (PDGF) inhibitors abrogated cancer cell growth enhanced by cervical cancer-associated fibroblast (CCF) coculture. Furthermore, tumor formation in a mouse xenograft model was enhanced by cotransplantation of CCF or mouse embryonic fibroblasts but not with embryonic fibroblasts from HB-EGF-deficient mice. Conversely, conditioned medium from cancer cells induced HB-EGF expression in CCF and mechanistic investigations established that PDGF was the primary factor responsible. Together, our findings indicate that HB-EGF and PDGF reciprocally mediate the interaction of cancer cells with cancer-associated fibroblasts, promoting cancer cell proliferation in a paracrine manner that has implications for novel combinatorial cancer. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 1516. doi:1538-7445.AM2012-1516
Prevention of Invasive Group A Streptococcal Disease Among Household Contacts of Case-Patients: Is Prophylaxis Warranted?
Authors: None The Working Group on Prevention of Invasive Group A Streptococcal Infections
Journal: JAMA (1998)

Objectives.—The Centers for Disease Control and Prevention (CDC) convened a Working Group in October 1995 to summarize the data regarding the risk of invasive group A streptococcal (GAS) disease among household contacts of an index patient and the potential efficacy of chemoprophylaxis. This statement on chemoprophylaxis for prevention of subsequent cases among household contacts is intended for use by public health professionals and clinicians.Participants.—The CDC invited representatives of the American Academy of Pediatrics, the Council of State and Territorial Epidemiologists, the Hospital Infection Control Practice Advisory Committee, the Infectious Diseases Society of America, and experts from academia to participate.Evidence.—Data on the transmission of GAS and risk factors for severe infection were considered. Population-based surveillance data were used to estimate the risk of invasive GAS disease among household contacts of a case patient. The potential efficacy of chemoprophylaxis was considered using estimates of the efficacy of various regimens in eradicating pharyngeal carriage.Consensus Process.—This document summarizes the data considered by the Working Group to develop its position. The consensus achieved by group discussion at the meeting was incorporated in a draft document, which was reviewed by all members and revised to include suggested changes.Conclusions.—The Working Group concluded that no definite recommendations can be made at this time regarding chemoprophylaxis for household contacts of persons with invasive GAS infection. More data are needed to assess the risk of subsequent cases and to determine an optimal regimen for chemoprophylaxis. Until such data are available, physicians and health departments should base decisions regarding chemoprophylaxis on their assessment of the risk associated with each individual case.
Acute myoglobinuria with or without drug usage
Authors: M. A. Tuller
Journal: JAMA (1971)

<h3>To the Editor.—</h3> The report of Richter et al on myoglobinuria associated with heroin addiction (<b>216</b>:1172 1971) described four patients with a syndrome involving skeletal muscles which was both clinically and pathologically distinctive. In each instance, onset of illness followed heroin use. Two of the four developed renal failure, presumably related to myoglobinuria. In one, death followed ten days of coma. With these exceptions, dysfunction of other organ systems was not striking, nor were there notable alterations in blood chemistry values (excluding, of course, elevation of enzyme levels reflecting muscle necrosis). Since May 1970, I have personally seen 17 patients with rhabdomyolysis and myoglobinuria,<sup>1</sup>15 at the Queens Hospital Center, two at the Long Island Jewish Medical Center. The diffuse inflammation of muscle described by Richter was the same, and the microscopic abnormalities in my patients were identical to those illustrated in their article. In no case could